The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes

Trends in Endocrinology and Metabolism

Volumn 28, Issue 8, 2017, Pages 626-636

  Guida, Claudia ^a   Stephen, Sam ^a   Guitton, Romain ^b   Ramracheya, Reshma D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

bariatric surgery; diabetes; incretins; peptide tyrosine tyrosine (PYY)

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON; INSULIN; PEPTIDE YY; GLUCOSE;

BARIATRIC SURGERY; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; HOMEOSTASIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; GLUCOSE; HOMEOSTASIS; HUMANS; ISLETS OF LANGERHANS; PEPTIDE YY;

EID: 85019939659     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.04.005     Document Type: Review

References (102)

1. Herbst, C.A., et al. Gastric bariatric operation in insulin-treated adults. Surgery 95 (1984), 209–214.
2. Pories, W.J., et al. Is type II diabetes mellitus (NIDDM) a surgical disease?. Ann. Surg. 215 (1992), 633–643.
3. Pories, W.J., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222 (1995), 339–352.
4. Buchwald, H., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122 (2009), 248–256.
5. Williams, S., et al. Surgical treatment of metabolic syndrome. Med. Princ. Pract. 21 (2012), 301–309.
6. Lim, E.L., et al. Reversal of type 2 diabetes: normalisation of β cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54 (2011), 2506–2514.
7. Laferrere, B., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93 (2008), 2479–2485.
8. Moncada, R., et al. Metabolic surgery enters the T2DM treatment algorithm. Trends Endocrinol. Metab. 27 (2016), 678–680.
9. Rubino, F., et al. Metabolic surgery in the treatment algorithm for Type 2 diabetes: a joint statement by international diabetes organizations. Surg. Obes. Relat. Dis. 12 (2016), 1144–1162.
10. American Diabetes Association, 7. Obesity management for the treatment of type 2 diabetes. Diabetes Care 40 (2017), S57–S63.
11. Schauer, P.R., et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N. Engl. J. Med. 376 (2017), 641–651.
12. Batterham, R.L., Cummings, D.E., Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39 (2016), 893–901.
13. Ballantyne, G.H., Peptide YY(1–36) and peptide YY(3–36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes. Surg. 16 (2006), 795–803.
14. Jacobsen, S.H., et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and β-cell function within 2 weeks after gastric bypass in nondiabetic subjects. Obes. Surg. 22 (2012), 1084–1096.
15. Meek, C.L., et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 77 (2016), 28–37.
16. Holst, J.J., Madsbad, S., Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg. Obes. Relat. Dis. 12 (2016), 1236–1242.
17. Ramracheya, R.D., et al. PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Rep. 15 (2016), 944–950.
18. Dutia, R., et al. Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 63 (2014), 1214–1223.
19. Korner, J., et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg. Obes. Relat. Dis. 3 (2007), 597–601.
20. Jorgensen, N.B., et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62 (2013), 3044–3052.
21. Salehi, M., et al. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60 (2011), 2308–2314.
22. Woerle, H.J., et al. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61 (2012), 2349–2358.
23. Ye, J., et al. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am. J. Physiol. Regul. Integr. Comp. Physiol. 306 (2014), R352–R362.
24. Wilson-Perez, H.E., et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes 62 (2013), 2380–2385.
25. Mokadem, M., et al. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol. Metab. 3 (2014), 191–201.
26. Pournaras, D.J., et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes. Surg. 20 (2010), 56–60.
27. Clements, R.H., et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am. Surg. 70 (2004), 1–5.
28. Rubino, F., et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann. Surg. 240 (2004), 236–242.
29. Isbell, J.M., et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 33 (2010), 1438–1442.
30. Jimenez, A., et al. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann. Surg. 257 (2013), 894–899.
31. Molin Netto, B.D., et al. Early effects of Roux-en-Y gastric bypass on peptides and hormones involved in the control of energy balance. Eur. J. Gastroenterol. Hepatol. 28 (2016), 1050–1055.
32. Svane, M.S., et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int. J. Obes. 40 (2016), 1699–1706.
33. McLaughlin, J.T., McKie, S., Human brain responses to gastrointestinal nutrients and gut hormones. Curr. Opin. Pharmacol. 31 (2016), 8–12.
34. Bottcher, G., et al. Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 4 (1989), 282–288.
35. Bottcher, G., et al. Peptide YY in the mammalian pancreas: immunocytochemical localization and immunochemical characterization. Regul. Pept. 43 (1993), 115–130.
36. Khan, D., et al. Islet distribution of peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human β-cell function and survival. Mol. Cell. Endocrinol. 436 (2016), 102–113.
37. Upchurch, B.H., et al. Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development 120 (1994), 245–252.
38. Schonhoff, S., et al. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol. Cell. Biol. 25 (2005), 4189–4199.
39. Amisten, S., et al. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol. Ther. 139 (2013), 359–391.
40. Pittner, R.A., et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28 (2004), 963–971.
41. Ahren, B., Larsson, H., Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. Eur. J. Endocrinol. 134 (1996), 362–365.
42. Shi, Y.C., et al. Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice. Endocrinology 156 (2015), 3122–3136.
43. Sam, A.H., et al. Selective ablation of peptide YY cells in adult mice reveals their role in β cell survival. Gastroenterology 143 (2012), 459–468.
44. Liu, G., et al. PYY in the expanding pancreatic epithelium. Endocrine 30 (2006), 103–112.
45. Eliasson, L., et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J. Gen. Physiol. 121 (2003), 181–197.
46. Wang, X., et al. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142 (2001), 1820–1827.
47. Mannon, P.J., Raymond, J.R., The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells. Biochem. Biophys. Res. Commun. 246 (1998), 91–94.
48. Cho, Y.R., Kim, C.W., Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation. Biochem. Biophys. Res. Commun. 314 (2004), 773–780.
49. Hansel, D.E., et al. Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (2001), 940–944.
50. Mannon, P.J., Peptide YY as a growth factor for intestinal epithelium. Peptides 23 (2002), 383–388.
51. Mannon, P.J., Mele, J.M., Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J. 350:Pt 3 (2000), 655–661.
52. Doyle, M.E., Egan, J.M., Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113 (2007), 546–593.
53. Lavine, J.A., Attie, A.D., Gastrointestinal hormones and the regulation of β-cell mass. Ann. N. Y. Acad. Sci. 1212 (2010), 41–58.
54. Lindqvist, A., et al. Gastric bypass improves β-cell function and increases β-cell mass in a porcine model. Diabetes 63 (2014), 1665–1671.
55. Service, G.J., et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 353 (2005), 249–254.
56. Patti, M.E., et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48 (2005), 2236–2240.
57. Meier, J.J., et al. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased β-cell turnover. Diabetes Care 29 (2006), 1554–1559.
58. Tito, J.M., et al. Peptide YY ameliorates cerulein-induced pancreatic injury in the rat. Am. J. Surg. 165 (1993), 690–696.
59. Li, Y., et al. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J. Biol. Chem. 278 (2003), 471–478.
60. Wideman, R.D., et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 13468–13473.
61. MacDonald, P.E., et al. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased β-cell mass in mice lacking the p110 gamma isoform of phosphoinositide 3-kinase. Endocrinology 145 (2004), 4078–4083.
62. Li, L.X., et al. Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. Endocrinology 147 (2006), 3318–3325.
63. MacDonald, P., Control of secretory granule access to the plasma membrane by PI3 kinase-gamma. Islets 1 (2009), 266–268.
64. Goldberg, Y., et al. Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am. J. Physiol. 275:5 Pt 1 (1998), C1207–C1215.
65. Robidoux, J., et al. Human syncytiotrophoblast NPY receptors are located on BBM and activate PLC-to-PKC axis. Am. J. Physiol. 274:3 Pt 1 (1998), E502–E509.
66. Lecat, S., et al. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor. Cell Signal. 27 (2015), 1297–1304.
67. Kolic, J., et al. Insulin secretion induced by glucose-dependent insulinotropic polypeptide requires phosphatidylinositol 3-kinase γ in rodent and human β-cells. J. Biol. Chem. 289 (2014), 32109–32120.
68. Campbell, J.E., Drucker, D.J., Islet α cells and glucagon – critical regulators of energy homeostasis. Nat. Rev. Endocrinol. 11 (2015), 329–338.
69. Lee, Y., et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14972–14976.
70. Dunning, B.E., et al. α cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48 (2005), 1700–1713.
71. Heller, R.S., et al. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 46 (1997), 785–791.
72. Tornehave, D., et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 56 (2008), 841–851.
73. Bagger, J.I., et al. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes. Metab. 13 (2011), 965–971.
74. Papamargaritis, D., et al. Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surg. Obes. Relat. Dis. 9 (2013), 192–201.
75. Nannipieri, M., et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98 (2013), 4391–4399.
76. Kashyap, S.R., et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36 (2013), 2175–2182.
77. Karamanakos, S.N., et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann. Surg. 247 (2008), 401–407.
78. Major, P., et al. Changes in levels of selected incretins and appetite-controlling hormones following surgical treatment for morbid obesity. Wideochir. Inne Tech. Maloinwazyjne 10 (2015), 458–465.
79. Tsoli, M., et al. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg. Obes. Relat. Dis. 9 (2013), 667–677.
80. Penney, N.C., et al. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int. J. Obes. 39 (2015), 1565–1574.
81. Federico, A., et al. Gastrointestinal hormones, intestinal microbiota and metabolic homeostasis in obese patients: effect of bariatric surgery. In Vivo 30 (2016), 321–330.
82. Tremaroli, V., et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22 (2015), 228–238.
83. Chimerel, C., et al. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 9 (2014), 1202–1208.
84. den Besten, G., et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54 (2013), 2325–2340.
85. Larraufie, P., et al. TLR ligands and butyrate increase Pyy expression through two distinct but inter-regulated pathways. Cell Microbiol., 19, 2017, e12648.
86. van der Schaar, H.M., et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog., 4, 2008, e1000244.
87. Batterham, R.L., et al. Inhibition of food intake in obese subjects by peptide YY3–36. N. Engl. J. Med. 349 (2003), 941–948.
88. Viardot, A., et al. Abnormal postprandial PYY response in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes. Int. J. Obes. 32 (2008), 943–948.
89. Loh, K., et al. Regulation of energy homeostasis by the NPY system. Trends Endocrinol. Metab. 26 (2015), 125–135.
90. Teubner, B.J., Bartness, T.J., PYY(3–36) into the arcuate nucleus inhibits food deprivation-induced increases in food hoarding and intake. Peptides 47 (2013), 20–28.
91. Ballantyne, G.H., Peptide YY(1–36) and peptide YY(3–36): Part I. Distribution, release and actions. Obes. Surg. 16 (2006), 651–658.
92. Batterham, R.L., et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418 (2002), 650–654.
93. Chandarana, K., et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 60 (2011), 810–818.
94. Meguid, M.M., et al. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition 24 (2008), 832–842.
95. Chandarana, K., et al. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol. Metab. 2 (2013), 142–152.
96. Hayes, J., et al. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug. Des. Dev. Ther 10 (2016), 2263–2270.
97. Naidoo, P., et al. Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes – a randomized, double-blind, double-arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study. JMIR Res. Protoc., 5, 2016, e145.
98. Holst, J.J., Deacon, C.F., Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48 (2005), 612–615.
99. Pospisilik, J.A., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003), 741–750.
100. Shah, P., et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J. Clin. Endocrinol. Metab. 98 (2013), E1163–E1172.
101. Nauck, M.A., El-Ouaghlidi, A., The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 (2005), 608–611.
102. Aaboe, K., et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 12 (2010), 323–333.